Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects

AIMS: This investigation characterised tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 antibody TAK‐079. METHODS: A randomised, double‐blind, placebo‐controlled trial of a single intravenous (i.v.) infusion or subcutaneous (s.c.) injection of TAK‐079 at escalating doses in healt...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Clin Pharmacol
Main Authors: Fedyk, Eric R., Zhao, Lin, Koch, Annelize, Smithson, Glennda, Estevam, Jose, Chen, Grace, Lahu, Gezim, Roepcke, Stefan, Lin, Jianchang, Mclean, Lachy
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7319013/
https://ncbi.nlm.nih.gov/pubmed/32045493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14241
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares